Genrix (shanghai) Biopharmaceutical Co., Ltd.

This phase 3 trial is testing a new drug called GR1803 against a standard three-drug combination (daratumumab, pomalidomide, and dexamethasone) in people with multiple myeloma that has come back after 1 to 3 prior treatments. About 358 participants will be randomly assigned to re…

This study tests a new biologic drug called GR1803 in 44 people with systemic lupus erythematosus, an autoimmune disease. The main goal is to check safety and see if the drug can control lupus activity. Participants must have moderate to severe lupus and have tried standard treat…

This Phase 3 trial tests an injection called GR1802 for people with seasonal allergic rhinitis (hay fever) that is not well controlled by standard treatments. The drug is a lab-made antibody that blocks a key inflammation signal. About 150 adults will receive either GR1802 or a p…

This early-stage study is testing a new drug, GR2303, in 64 healthy adults to see if it is safe and how the body handles it. Participants will receive either the drug or a placebo and be monitored for side effects. This study does not aim to treat any disease.